Thank you to our panelists for the great discussion about the live attenuated influenza vaccine (LAIV). To build on some of the points that were already made, the next question relates to the the varying effectiveness of LAIV between populations.
As noted by Dr. Cowling, in contrast to the US, in the UK the LAIV has been shown to be effective against influenza A(H1N1)pdm09. Similarly, in a recently published cluster randomized controlled trial among Hutterite children in Canada (Loeb et al., Ann Intern Med 2016), LAIV was non-inferior to inactivated influenza vaccine (IIV) when analyzed across all influenza subtypes. However, in this trial the LAIV vaccinated individuals did experience more influenza A infections compared to IIV vaccinated individuals, but this difference seems to have been driven largely by influenza A(H3N2) and not A(H1N1)pdm09. Of note, in the latter study, the investigators used LAIV3 because the quadrivalent vaccine was unavailable.
What could account for the varying performance of LAIV across diverse settings/populations?
Easy one-click social registrationIs this safe?
We only receive the minimum information necessary to verify your account. We never get access to your friends/contacts or your profile, and we never post on your behalf. Your social account is used for logging in only.ORRegister via email
Send me updates on this Contest
In order to ensure a fair voting process and to make sure that no one votes more than once, we ask that you register either with a social networking account (easiest, only requires one click) or by registering with your email address (this will require you to click on a verification email that we will send you).
You only need to register once.